• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Litorva 10, 20, 40, 80 mg
    / Dexcel


    Active Ingredient
    Atorvastatin (as Calcium) 10, 20, 40, 80 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    30 X 10 mg

    partial basket chart 26467 12449

    Tablets

    30 X 20 mg

    partial basket chart 26468 12450

    Tablets

    30 X 40 mg

    partial basket chart 26469 12451

    Tablets

    30 X 80 mg

    partial basket chart 34561 12464

    Related information


    Dosage

    Usual initial dose: 10 or 20mg 1 × daily. Dosage adjustment will be at intervals of 4 weeks or more. Maximum dose for adults: 80mg 1xdaily. Maximum dose for children: 20 mg 1Xdaily. Doses may be given at any time of day without regard to meals. Lipid levels should be analyzed within 2-4 weeks and dosage adjustment accordantly.
    For additional information, please contact the license holder.


    Indications

    Litorva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Litorva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable.
    Pediatric patients (10-17 years of age): Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present:
    1. LDL-C remains >or = 190 mg/dl or
    2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient.
    Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor.
    In patients with clinically evident coronary heart disease, Litorva is indicated to: Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
    For additional information, please contact the license holder.


    Contra-Indications

    Hypersensitivity to Atorvastatin or other ingredients or to similar blood lipid lowering. During pregnancy, while breast feeding and in woman of childbearing age not using adequate contraceptive measures. Active or history of liver disease, unexplained presistent elevation  serum transaminase exceeding 3 times the upper limit of normal. Myopathy. Pediatric under 10 years and premenstruation girls. Patients that take Cyclosporine, Telaprevir or a combination of Tipranavir and Ritronavir.
    For additional information, please contact the license holder.


    Special Precautions

    For additional information, please contact the license holder.


    Side Effects

    For additional information, please contact the license holder.


    Drug interactions

    For additional information, please contact the license holder.


    Pregnancy and Lactation

    For additional information, please contact the license holder.


    Overdose

    For additional information, please contact the license holder.


    Manufacturer
    Dexcel Ltd.
    Licence holder
    CLOSE